Adicet Bio (ACET) President & CEO Chen Schor Buys 55,000 Shares

Chen Schor, the President and CEO of ACET, recently bought 55,000 shares of the company on June 19, 2026. This insider transaction was not part of a pre-arranged trading plan, indicating a personal decision to invest in the company.

Other Institutional Activity in ACET

RA Capital Management, L.P. increased its stake in ACET by 234,375 shares, bringing its total to 1,182,624 shares valued at about $8.05 million, a 24.7% increase. Meanwhile, Citadel Advisors LLC boosted its holdings by 274,009 shares to 381,823 shares, marking a significant 254.1% increase, with a total value of approximately $2.6 million. Vanguard Capital Management LLC opened a new position with 336,524 shares worth around $2.29 million. On the other hand, Woodline Partners LP reduced its holdings by 311,876 shares, ending with 313,124 shares valued at $2.13 million, a decrease of 49.9%.

Adicet Bio, Inc. Stock Down 9.6%

Shares of ACET traded near $8.35 on Wednesday. The stock has seen varied activity from institutional investors, indicating differing views on its potential. While some funds are increasing their stakes, others are reducing or opening new positions.

Insider Buying and Selling at Adicet Bio, Inc.

In addition to Chen Schor's purchase, several other insiders acquired shares on June 21, 2026. Lloyd Klickstein, Jeffrey Chodakewitz, Steve Dubin, Andrew Sinclair, Michael Grissinger, and Katie Peng each bought 4,200 shares. These transactions were also not part of any pre-arranged trading plans, suggesting a shared confidence in the company's prospects among its leadership.

Analysts Set New Price Targets

On May 5, 2026, Jefferies assumed coverage of ACET with a 'buy' rating and set a price target of $19. HC Wainwright & Co. maintained its 'buy' rating with a target of $27 as of March 23, 2026. These positive ratings reflect a strong analyst consensus on the stock's potential, with targets suggesting significant upside from current levels.

Bottom Line

Chen Schor's recent purchase of ACET shares, along with other insider buys, signals a positive outlook from the company's leadership. Institutional activity shows a mix of increased stakes and new positions, reflecting varied investor sentiment. Analyst ratings remain optimistic, with multiple 'buy' recommendations and high price targets, suggesting potential growth for the stock. As always, it's important to remember that insider and institutional trades are backward-looking indicators and may not reflect current positions.